Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,992
-5.17%
|
$303,696
$38.49 P/Share
|
|
Aug 08
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,992
+4.91%
|
$231,768
$29.62 P/Share
|
|
Jun 17
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
15,000
-9.63%
|
$435,000
$29.5 P/Share
|
|
Jun 13
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
26,132
-6.72%
|
$731,696
$28.45 P/Share
|
|
May 27
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
8,748
-4.67%
|
$253,692
$29.0 P/Share
|
|
May 23
2025
|
Anthony B. Semedo Director |
SELL
Open market or private sale
|
Direct |
2,600
-7.29%
|
$72,800
$28.47 P/Share
|
|
May 22
2025
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+11.41%
|
-
|
|
May 22
2025
|
Anthony B. Semedo Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+13.09%
|
-
|
|
May 22
2025
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.65%
|
-
|
|
May 22
2025
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.05%
|
-
|
|
May 22
2025
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.04%
|
-
|
|
May 22
2025
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+10.52%
|
-
|
|
May 22
2025
|
Elizabeth A Hoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+16.77%
|
-
|
|
May 22
2025
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+8.44%
|
-
|
|
May 21
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
9,926
-5.03%
|
$287,854
$29.0 P/Share
|
|
May 09
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
10,548
-4.66%
|
$305,892
$29.13 P/Share
|
|
Mar 11
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
18,020
-8.37%
|
$414,460
$23.61 P/Share
|
|
Mar 11
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,092
+8.15%
|
$400,932
$21.55 P/Share
|
|
Mar 11
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,100
-6.74%
|
$347,300
$23.61 P/Share
|
|
Mar 11
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,910
+6.64%
|
$334,110
$21.55 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
88,439
-4.79%
|
$2,122,536
$24.78 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,615
+7.47%
|
$1,587,915
$21.55 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,701
+11.64%
|
-
|
|
Mar 06
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,048
-0.71%
|
$25,152
$24.8 P/Share
|
|
Mar 06
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,261
+6.5%
|
-
|
|
Mar 06
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,618
-1.24%
|
$62,832
$24.8 P/Share
|
|
Mar 06
2025
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,654
+10.86%
|
-
|
|
Mar 06
2025
|
Lance A Berry Executive VP, CFO |
SELL
Open market or private sale
|
Direct |
4,909
-3.1%
|
$117,816
$24.8 P/Share
|
|
Mar 06
2025
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
48,100
+23.3%
|
-
|
|
Mar 06
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,124
-1.07%
|
$50,976
$24.8 P/Share
|
|
Mar 06
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,493
+11.39%
|
-
|
|
Mar 06
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
1,603
-1.36%
|
$38,472
$24.8 P/Share
|
|
Mar 06
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
19,240
+14.07%
|
-
|
|
Mar 05
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
472
-0.27%
|
$11,800
$25.29 P/Share
|
|
Mar 05
2025
|
Anthony B. Semedo Director |
BUY
Open market or private purchase
|
Indirect |
600
+50.0%
|
$15,000
$25.25 P/Share
|
|
Mar 05
2025
|
Anthony B. Semedo Director |
BUY
Open market or private purchase
|
Direct |
1,500
+4.04%
|
$37,500
$25.33 P/Share
|
|
Feb 28
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,297
+4.38%
|
-
|
|
Feb 28
2025
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,524
+11.44%
|
-
|
|
Feb 28
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
18,398
+15.77%
|
-
|
|
Feb 28
2025
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,301
+11.61%
|
-
|
|
Feb 28
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,416
+11.91%
|
-
|
|
Feb 28
2025
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
34,435
+23.8%
|
-
|
|
Feb 24
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,323
-0.62%
|
$89,721
$27.31 P/Share
|
|
Feb 24
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
42,156
-1.53%
|
$1,138,212
$27.31 P/Share
|
|
Feb 24
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,335
-0.87%
|
$144,045
$27.31 P/Share
|
|
Feb 24
2025
|
Lance A Berry Executive VP, CFO |
SELL
Open market or private sale
|
Direct |
3,259
-4.12%
|
$87,993
$27.31 P/Share
|
|
Feb 24
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,457
-0.98%
|
$174,339
$27.31 P/Share
|
|
Feb 24
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
4,687
-1.41%
|
$126,549
$27.31 P/Share
|
|
Dec 12
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
1,100
-0.81%
|
-
|
|
Dec 11
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
8,070
-2.52%
|
$242,100
$30.13 P/Share
|